Fig. 7: TIS-associated PU.1 drives antigen presentation and expression of immune checkpoint molecules.
From: Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control
a InnateDB KEGG and REACTOME pathway overrepresentation analysis78 of therapy induced senescence (TIS)-associated PU.1 targets. Hypergeometric distribution test, Benjamini-Hochberg multiple testing corrected P values for each pathway are shown. See Supplementary Data 5 for scored transcripts. Terms relevant for tumor immunity in bold. b Flow cytometry analysis of MHC class II (top) and CD86 (bottom) expression on untreated (UT) and 5-day adriamycin (ADR)-exposed control;bcl2 lymphomas, transduced with a Spi1 targeting (sh_Spi1) or control shRNA (sh_ctrl) (n = 10 individual lymphomas each). c Flow cytometry analysis of PD-L1 (CD274) expression on individual UT and 5-day ADR-exposed control;bcl2 lymphomas, gated by CD11b (n = 12, top) or CD115 (n = 7, bottom) expression. d qRT-PCR-determined expression of Cd274 and Pdcd1lg2 (encoding PD-L2) in individual ADR-exposed control;bcl2 lymphomas, FACS-sorted by CD115 expression (n = 5; samples as in Fig. 2c). Bars represent the mean fold-change relative to matched UT lymphomas ± SEM. e As in b, but analyzing surface PD-L1 expression. b, c, e Data points are isotype-corrected MFI values and bars represent the average mean fluorescence intensity (MFI) ± SEM. P-values by two-sided, paired t-test. Source data are provided in the Source Data file.
